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We have recently demonstrated that signal transduc-
ers and activators of transcription (STATs) 1, 3, 5A, 5B,
and 6 are expressed in both cultured and native adipo-
cytes. Our current studies have focused on the activa-
tion of STATs 1 and 3 by leukemia inhibitory factor
(LIF), oncostatin-M (OSM), and interferon-g (IFNg) in
3T3-L1 adipocytes. IFNg is shown to be a potent activa-
tor of STAT 1 as indicated by both tyrosine phosphoryl-
ation and nuclear translocation. However, LIF and
OSM, which are potent inducers of STAT 3, are less
potent activators of STAT 1 as measured by both tyro-
sine phosphorylation and nuclear translocation. Both
STATs 1 and 3 were translocated to the nucleus in a
time-dependent fashion following LIF treatment. In ad-
dition, IFNg resulted in a time- and dose-dependent ef-
fect on STATs 1 and 3 nuclear translocation. Growth
hormone, a potent activator of STATs 5A and 5B, had a
minimal effect on STAT 1 and STAT 3 tyrosine phospho-
rylation. Preincubation with either insulin or growth
hormone had no detectable effects on the tyrosine phos-
phorylation or nuclear translocation of STATs 1 and 3
induced by LIF, OSM, or IFNg. The effects of LIF and
IFNg on STAT 1 and 3 tyrosine phosphorylation and
nuclear translocation were confirmed in native rat adi-
pocytes. In 3T3-L1 adipocytes, a low level of serine phos-
phorylation of STAT 3 on residue 727 was observed and
was markedly enhanced by insulin, LIF, or OSM. This
increase in STAT 3 Ser727 phosphorylation was depend-
ent upon the activation of MAPK, since the MAPK ki-
nase inhibitor (PD98059) reduced STAT 3 Ser727 phos-
phorylation to basal levels. The inhibition of MAPK had
no effect on the ability of STATs 1 and 3 to be tyrosine-
phosphorylated or translocate to the nucleus. These
studies demonstrate the highly specific and quantita-
tive activation of STATs 1 and 3 by LIF, OSM, and IFNg
in adipocytes and indicate that STAT 3 is a substrate for
MAPK in adipocytes.
The signal transducer and activator of transcription (STAT)1
family of transcription factors is composed of seven family
members (STATs 1, 2, 3, 4, 5A, 5B, and 6) that, in response to
stimulation of various receptors, mainly those for cytokines,
are phosphorylated on tyrosine residues, which causes their
translocation to the nucleus. Each STAT family member shows
a distinct pattern of activation by cytokines and upon nuclear
translocation can regulate the transcription of particular genes
(1). The order of events for STAT activation can be briefly
described as follows: 1) ligand binding of cell surface receptor;
2) receptor association with a Janus kinase family member; 3)
Janus kinase tyrosine phosphorylation of STAT proteins; 4)
dimerization of the STATs; 5) translocation to the nucleus; and
6) DNA binding. STATs have been shown to bind at least three
different DNA consensus sequences, and this binding regulates
the transcription of specific genes (1, 2). It has also been dem-
onstrated that STATs can be activated independently of Janus
kinases (1, 3) and that serine phosphorylation may also con-
tribute to the ability of STATs to regulate transcription (4, 5).
Many recent studies suggest that the activation of particular
STAT proteins may vary depending upon the cell type (1).
Moreover, the tissue distribution of each STAT is unique, sug-
gesting that the regulation of tissue-specific gene expression
may be a physiological role for these proteins. This is supported
by numerous reports that demonstrate that particular STATs
are activated differently in response to growth factors and
cytokines depending upon the cell type. Transgenic knockout
experiments have revealed crucial roles for each known mam-
malian STAT (1), and cell-specific functions for STAT family
members have been identified. To date, the activation of STAT
proteins in adipocytes has not been extensively investigated.
Oncostatin-M (OSM) and leukemia inhibitory factor (LIF)
are recently identified cytokines that share many structural
and genetic features and are both mediators of pleiotropic
biological activities (6). LIF and OSM have effects on a wide
variety of cell types and are known activators of STATs 1, 3,
and 5 (7–9, 11–13). The receptors for these cytokines consist of
the common signaling subunit, gp130, to which other subunits
are added to modify ligand specificity. In adipocytes, LIF has
been shown to induce changes in lipid metabolism (14–16) and
modulate the transcriptional regulation of lipoprotein lipase
(15). Interferon-g (IFNg), which is primarily known for its roles
in immunological responses, has also been shown to have po-
tent effects on adipocyte gene expression (17) and inhibit the
differentiation of cultured rodent preadipocytes (18). IFNg has
been shown to activate specific proteins in certain cell types.
For example, IFNg activates STAT 1 but not STAT 3 in some
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cell types (19, 20) and activates only STAT 5 in U937 cells (21).
In our studies, we have identified LIF, OSM, and IFNg as
inducers of STAT 1 and 3 tyrosine phosphorylation and nuclear
translocation in 3T3-L1 adipocytes. Highly specific and time-
dependent activation of STATs 1 and 3 by LIF and IFNg was
observed. Pretreatment of adipocytes with either growth hor-
mone or insulin had no effect on the ability of LIF, OSM, and
IFNg to result in STAT 1 and 3 tyrosine phosphorylation or
nuclear translocation. We have also demonstrated that a crit-
ical serine residue in STAT 3, serine 727, is phosphorylated to
a small extent in unstimulated serum-deprived 3T3-L1 adipo-
cytes. LIF and OSM, which are known activators of the p42/44
mitogen activated protein kinase/extracellular regulated ki-
nase (MAPK) (22, 23), markedly enhanced STAT 3 Ser727 phos-
phorylation in 3T3-L1 adipocytes. Furthermore, the induction
of STAT 3 Ser727 phosphorylation by LIF, OSM, and insulin
was dependent upon the presence of active MAPK. In sum-
mary, these studies have examined the mechanisms of STAT 1
and 3 signal transduction by potent activators of these tran-
scription factors in adipocytes.
EXPERIMENTAL PROCEDURES
Materials—Dulbecco’s modified Eagle’s medium (DMEM) and DNase
I were purchased from Life Technologies, Inc. Bovine and fetal bovine
serum were obtained from Sigma and Life Technologies, respectively.
Epidermal growth factor (EGF) was purchased from Biosource Inter-
national and Sigma. Murine granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF) and murine LIF were from Life Technologies.
Insulin, OSM, platelet-derived growth factor (PDGF-BB), and growth
hormone (GH) were purchased from Sigma. Murine IFNg, insulin-like
growth factor I, interleukin (IL)-6, and IL-4 were purchased from Boeh-
ringer Mannheim. PD98059, the mitogen-activated protein kinase ki-
nase inhibitor, was purchased from Research Biochemicals Interna-
tional. The non-phospho-STAT antibodies were monoclonal IgGs
purchased from Transduction Laboratories or polyclonal IgGs from
Quality Controlled Biochemicals Inc. Highly phosphospecific polyclonal
antibodies for STAT 1 (Tyr701) and STAT 3 (Tyr705 and Ser727) were
provided by Quality Controlled Biochemicals. Antiactive dual phos-
phospecific MAPK (ERK1/ERK2) antibody was a polyclonal IgG from
Promega, and ERK 1/ERK2 was a rabbit polyclonal antibody from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Cell Culture—Murine 3T3-L1 preadipocytes were plated and grown
to 2 days postconfluence in DMEM with 10% bovine serum. Medium
was changed every 48 h. Cells were induced to differentiate by changing
the medium to DMEM containing 10% fetal bovine serum, 0.5 mM
3-isobutyl-1-methylxanthine, 1 mM dexamethasone, and 1.7 mM insulin.
After 48 h, this medium was replaced with DMEM supplemented with
10% fetal bovine serum, and cells were maintained in this medium until
utilized for experimentation. Prior to experimentation, cells were se-
rum-deprived in DMEM containing 0.2% fatty acid-free and growth
factor-depleted bovine serum albumin (Sigma) for 12 h as we have
previously described (24).
Preparation of Whole Cell Extracts—Serum-deprived 3T3-L1 adipo-
cytes were rinsed with phosphate-buffered saline and then harvested in
a nondenaturing buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1
mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% Nonidet P-40, 1 mM
phenylmethylsulfonyl fluoride, 1 mM pepstatin, 50 trypsin inhibitory
milliunits of aprotinin, 10 mM leupeptin, and 2 mM sodium vanadate.
Samples were extracted for 30 min on ice and then centrifuged at 15,000
rpm at 4 °C for 15 min. Supernatants containing whole cell extracts
were analyzed for protein content using a BCA kit (Pierce) according to
the manufacturer’s instructions.
Preparation of Nuclear/Cytosolic Extracts—Serum-deprived 3T3-L1
adipocytes were rinsed with phosphate-buffered saline and then har-
vested in a nuclear homogenization buffer containing 20 mM Tris (pH
7.4), 10 mM NaCl, and 3 mM MgCl2. Nonidet P-40 was added to a final
concentration of 0.15%, and cells were homogenized with 16 strokes in
a Dounce homogenizer. The homogenates were centrifuged at 1500 rpm
for 5 min. Supernatants were saved as cytosolic extract, and the nuclear
pellets were resuspended in 1⁄2 volume of nuclear homogenization buffer
and were centrifuged as before. The pellet of intact nuclei was resus-
pended again in 1⁄2 of the original volume of nuclear homogenization
buffer and centrifuged again. A small portion of the nuclei was used for
trypan blue staining to examine the integrity of the nuclei. The majority
of the pellet (intact nuclei) was resuspended in an extraction buffer
containing 20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5 mM MgCl2, 0.2
mM EDTA, and 25% glycerol. Nuclei were extracted for 30 min on ice
and then placed at room temperature for 10 min. Two hundred units of
DNase I was added to each sample, and tubes were inverted and
incubated for an additional 10 min at room temperature. Finally, the
sample was subjected to centrifugation at 15,000 rpm at 4 °C for 30 min.
Supernatants containing nuclear extracts were analyzed for protein
content.
Rat Adipocytes—Adipocytes were isolated from the epididymal fat
pads of male Sprague-Dawley rats (150–175 g) by collagenase digestion
as described (25). Whole cell extracts were prepared using the nonde-
naturing buffer listed above. Cell fractionation was performed by ho-
mogenizing native adipocytes in nuclear homogenization buffer. Follow-
ing homogenization, cytosolic and nuclear extracts were prepared from
native adipocytes in an identical fashion to the procedure described
above for the 3T3-L1 adipocytes.
Gel Electrophoresis and Immunoblotting—Proteins were separated
in 7.5 or 12% polyacrylamide (acrylamide from National Diagnostics)
gels containing SDS according to Laemmli (26) and transferred to
nitrocellulose (Bio-Rad) in 25 mM Tris, 192 mM glycine, and 20% meth-
anol. Following transfer, the membrane was blocked in 4% milk for 1 h
at room temperature. Results were visualized with horseradish perox-
idase-conjugated secondary antibodies (Sigma) and enhanced chemilu-
minescence (Pierce).
RESULTS
The phosphorylation of STATs 1 and 3 by known activators
of these proteins was investigated by treating serum-deprived
3T3-L1 adipocytes with a variety of growth factors and cyto-
kines and examining tyrosine phosphorylation and nuclear
translocation. Detection of the phosphorylated forms of STATs
1 and 3 was performed with antibodies specific for the tyrosine-
phosphorylated sites of these proteins on tyrosine 701 (STAT 1
Tyr701) and tyrosine 705 (STAT 3 Tyr705). The specificity of
these antibodies was verified by first immunoprecipitating the
proteins from serum-deprived 3T3-L1 adipocytes with antibod-
ies directed to alternate sites and immunoblotting with the
phosphorylation state-specific antibody (data not shown).
Whole cell, cytosolic, and nuclear extracts were analyzed
from 3T3-L1 adipocytes that were treated for 15 min with
IFNg, LIF, PDGF, EGF, GH, GM-CSF, IL-6, IL-4, or insulin-
like growth factor I. Immunoblotting of whole cell extracts (Fig.
1A) demonstrates that STAT 1 Tyr701 phosphorylation occurs
after acute treatment with either IFNg or LIF as indicated by
blotting with the specific STAT 1 Tyr701 polyclonal antibody
(STAT 1 p-tyr). The phosphorylation of STAT 3 Tyr705 was
most potently stimulated by LIF and to a lesser extent by IFNg
treatment. However, acute exposure to PDGF, GH, IL-6, and
IL-4 also resulted in detectable, albeit lower, levels of STAT 3
Tyr705 phosphorylation (STAT 3 p-tyr). Interestingly, EGF, a
potent activator of STATs 1 and 3 in other cell types, had no
effect on STAT 1 Tyr701 or STAT 3 Tyr705 phosphorylation in
serum-deprived 3T3-L1 adipocytes. The efficacy of EGF was
confirmed by examining the activation of ERK1/2 in the pres-
ence of EGF utilizing a commercially available, dual phos-
phospecific ERK1/2 antibody (Fig. 1A). Antibodies were also
used to confirm the consistent protein concentrations of STATs
1 and 3 and ERK1/2 during immunoblotting (Fig. 1A).
In the experiment described above, cytosolic and nuclear
extracts were also isolated from identically treated cells to
compare the tyrosine phosphorylation and nuclear transloca-
tion of STATs 1 and 3 with the tyrosine phosphorylation we
observed in whole cell extracts. As expected, both LIF and IFNg
resulted in the nuclear translocation of STAT 1 and the detec-
tion of Tyr701-phosphorylated STAT 1 in nuclear extracts (Fig.
1B). However, not all of the activators of STAT 3 Tyr705 phos-
phorylation resulted in detectable nuclear translocation of
STAT 3 (Fig. 1B). The bottom two parts of Fig. 1B indicate that
LIF and, to a lesser extent, IFNg resulted in the Tyr705 phos-
Distinct Activation of STATs 1 and 3 in Adipocytes 31409
phorylation and nuclear translocation of STAT 3. Prolonged
exposures of these STAT 3 immunoblots indicated the presence
of STAT 3 in the nucleus following LIF and IFNg stimulation
and to a much lesser extent by GH stimulation (data not
shown). Yet, there was no detectable STAT 3 in the nucleus
following stimulation by PDGF, EGF, IL-4, GM-CSF, IL-6 or
insulin-like growth factor I using antibodies directed against
either non-phospho-STAT 3 or STAT 3 Tyr705 polyclonal anti-
body. Therefore, we have focused our studies on the prominent
activation of STATs 1 and 3 by LIF and IFNg.
To further clarify the specific activation of STATs 1 and 3 by
IFNg, a dose- and time-dependent analysis of nuclear translo-
cation of adipocyte-expressed STATs was performed. Serum-
deprived 3T3-L1 adipocytes were treated for 15 min with eight
different doses of IFNg (0–1000 units/ml). Cells were harvested
as described under “Experimental Procedures,” and cytosolic
and nuclear extracts were examined for the presence of STAT
family members by Western blot analysis. As indicated in Fig.
2A, acute IFNg treatment resulted in a dose-dependent trans-
location of STATs 1 and 3 to the nucleus. However, IFNg had
no effect on STATs 5A, 5B, or 6 as indicated by the absence of
these proteins from the nucleus. In addition, adipocytes were
treated with 100 units/ml IFNg for various times, and the
presence of STATs 1 and 3 in the nucleus was examined. As
expected, the translocation of STATs 1 and 3 occurred between
3 and 15 min following IFNg stimulation (Fig. 2B). The pres-
ence of these proteins in the nucleus was sustained for 90 min,
with no detectable STAT proteins present in the nucleus after
120 min.
The specific activation of STATs 1 and 3 by LIF was also
investigated by examining tyrosine phosphorylation and nu-
clear translocation. Serum-deprived 3T3-L1 adipocytes were
treated with LIF for various periods and then fractionated into
cytosolic and nuclear extracts. As indicated by immunoblotting
extracts with STAT 1 Tyr701 polyclonal antibody and STAT 3
Tyr705 polyclonal antibody in Fig. 1, treatment with LIF re-
sulted in the phosphorylation of both STAT 1 Tyr701 and STAT
3 Tyr705. As demonstrated in the nuclear extract samples in the
top three panels of Fig. 3, the STAT 1 Tyr701 polyclonal anti-
body is more sensitive than the non-phospho-STAT 1 antibody.
However, analysis with either one of these antibodies demon-
strates that the presence of STAT 1 in the nucleus is maximal
following a 15-min LIF stimulation. Following a 5-min treat-
ment with LIF, there was a marked detection of phosphoryl-
ated STATs 1 and 3 in the cytosol (Fig. 3). Notably, there was
a concomitant loss of phosphorylated STATs 1 and 3 in the
cytosol with the appearance of phosphorylated STATs 1 and 3
in the nucleus. A rapid phosphorylation of STAT 3 Tyr705 is
FIG. 1. Tyrosine phosphorylation
and nuclear translocation of STATs 1
and 3 in 3T3-L1 adipocytes. Whole cell,
cytosolic, and nuclear extracts were pre-
pared from serum-deprived 3T3-L1 adipo-
cytes following a 15-min treatment with
IFNg (100 units/ml), LIF (0.5 nM), PDGF
(5 ng/ml), EGF (1 nM), GH (250 ng/ml),
GM-CSF (0.5 ng/ml), IL-6 (2 ng/ml), IL-4
(5 ng/ml), or insulin-like growth factor I
(15 ng/ml). Extracts were prepared as de-
scribed under “Experimental Proce-
dures.” One hundred mg of each extract
was separated by SDS-PAGE, transferred
to nitrocellulose, and subjected to West-
ern blot analysis. The STAT 1 Tyr701 poly-
clonal (STAT 1 p-tyr) and STAT 3 Tyr705
polyclonal (STAT 3 p-tyr) antibodies were
phosphospecific polyclonal IgGs. The
STAT 1 and STAT 3 antibodies were
monoclonal IgGs. The detection system
was horseradish peroxidase-conjugated
secondary antibodies (Sigma) and en-
hanced chemiluminescence (Pierce). This
is a representative experiment independ-
ently performed three times.
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shown in the two STAT 3 panels of Fig. 3, with maximal
accumulation in the nucleus following a 15–30-min LIF treat-
ment. We have previously reported that STAT 5A is present in
the nucleus of adipocytes under basal conditions (24), but LIF
treatment does not result in changes in the amount of this
protein in the nucleus (Fig. 3). Finally, neither STAT 5B nor
STAT 6 protein was detectable in the nucleus following LIF
treatment (Fig. 3).
FIG. 2. Dose- and time-dependent
effect of IFNg on STAT 1 and STAT 3
nuclear translocation. A, dose depend-
ence. Cytosolic and nuclear extracts were
prepared from fully differentiated 3T3-L1
adipocytes following a 15-min treatment
with various doses of IFNg. One hundred
mg of each extract was separated by SDS-
PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis. B,
time dependence. Cytosolic and nuclear
extracts were prepared from fully differ-
entiated 3T3-L1 adipocytes following
stimulation with 100 units/ml of IFNg for
various times (indicated at the top of B).
One hundred mg of each extract was sep-
arated by SDS-PAGE, transferred to ni-
trocellulose, and subjected to Western
blot analysis. Samples were processed,
and results were visualized as described
in the legend to Fig. 1. This is a represent-
ative experiment independently per-
formed three times.
FIG. 3. Time-dependent activation
of STATs 1 and 3 by LIF in 3T3-L1
adipocytes. Cytosolic and nuclear ex-
tracts were isolated from serum-deprived
3T3-L1 adipocytes following treatment
with LIF as indicated at the top. One hun-
dred mg of each extract was separated by
SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis.
Samples were processed, and results were
visualized as described in the legend to
Fig. 1. This is a representative experi-
ment independently performed two times.
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The activation of STATs 1 and 3 by LIF, OSM, and IFNg was
also investigated in native rat adipocytes, which were isolated
by collagenase digestion of epididymal fat pads. Isolated adi-
pocytes were stimulated for 10 min with insulin, leptin, LIF,
OSM, or IFNg. Tyrosine phosphorylation was examined by
immunoblotting of whole cell extracts with the STAT 1 Tyr701
polyclonal and STAT 3 Tyr705 polyclonal antibodies. Low, but
detectable, levels of STAT 1 and 3 tyrosine phosphorylation in
the untreated, insulin-treated, and leptin-treated rat adipo-
cytes were very similar. However, a substantial increase in the
phosphorylation of both STAT 1 Tyr701 and STAT 3 Tyr705 by
LIF, OSM, and IFNg was observed in whole cell extracts (Fig.
4A). These samples were also analyzed with the STAT 3 anti-
body to demonstrate that the observed increases in STAT 1 and
3 tyrosine phosphorylation were not due to differences in the
amount of protein present in each sample. We also examined
the nuclear translocation of STATs 1 and 3 by LIF and IFNg in
native rat adipocytes. Following acute stimulation, cells were
fractionated to obtain cytosolic and nuclear extracts. Acute
treatment with either LIF or IFNg resulted in a substantial
increase in STATs 1 and 3 in nuclear extracts (Fig. 4B).
We also examined the ability of pretreatment with either
insulin or GH to affect the tyrosine phosphorylation of STATs
1 and 3 by LIF, OSM, and IFNg. Serum-deprived 3T3-L1 adi-
pocytes were treated for 20 min with either 50 nM insulin or 100
ng/ml of GH and then treated for 15 min with OSM, LIF, or
IFNg. As previously indicated (Fig. 1), IFNg is a potent inducer
of STAT 1 Tyr701 phosphorylation but also results in STAT 3
Tyr705 phosphorylation and nuclear translocation of STAT 3
(Figs. 1 and 2). Activation of STATs 1 and 3 is clearly demon-
strated in Fig. 5, where IFNg is a potent activator of STAT 1
and LIF and OSM are potent activators of STAT 3. As indicated
in Fig. 5, GH resulted in a minimal amount of STAT 1 and
STAT 3 tyrosine phosphorylation, but preincubation with GH
or insulin did not have any effect on the phosphorylation of
STAT 1 Tyr701 or STAT 3 Tyr705 by LIF, OSM, or IFNg. These
whole extracts were also used to examine the presence of active
MAPK. As indicated in Fig. 5, insulin is a potent activator of
MAPK. In addition, GH, LIF, and OSM treatment also resulted
in the activation of MAPK. However, neither the tyrosine phos-
phorylation of STATs 1 and 3 (Fig. 5) nor the presence of STATs
1 and 3 in the nucleus (data not shown) correlated with the
activation of MAPK.
Recent studies have suggested that both STATs 1 and 3 are
substrates of MAPK and that serine phosphorylation of STATs
1 and 3 may affect both the nuclear translocation and DNA
binding of these transcription factors. Therefore, we examined
the ability of OSM, LIF, and IFNg to activate STATs 1 and 3 in
the presence of the mitogen-activated protein kinase kinase
inhibitor, PD98059. Serum-deprived 3T3-L1 adipocytes were
pretreated with 30 mM PD98059 for 30 min and then stimulated
with IFNg alone or IFNg and insulin for 15 min. Cytosolic,
nuclear, and whole cell extracts were examined for STAT 1 and
3 tyrosine phosphorylation as shown in Fig. 6. IFNg treatment
resulted in the tyrosine phosphorylation and nuclear translo-
cation of STATs 1 and 3, and this activation was not affected by
the addition of insulin either prior to or following IFNg treat-
ment. In the STAT 3 p-tyr panel, three different treatments
resulted in the presence of two distinct immunoreactive STAT
3 bands. These three treatments were from cells that were
FIG. 4. Tyrosine phosphorylation and nuclear translocation of
STATs 1 and 3 by LIF and IFNg in native rat adipocytes. Whole
cell, cytosolic, and nuclear extracts were prepared from adipocytes
isolated by collagenase digestion of rat epididymal fat pads. Panel A,
whole cell extracts were prepared following a 10-min stimulation with
50 nM insulin, leptin (25 ng/ml), OSM (0.5 ng/ml), LIF (0.5 nM), or IFNg
(100 units/ml). One hundred mg of each extract was separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis. B, cytosolic and nuclear extracts were prepared following a
15-min stimulation with either LIF or IFNg. One hundred mg of each
extract was separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis. Samples were processed, and results
were visualized as described in the legend to Fig. 1. This is a represent-
ative experiment independently performed two times.
FIG. 5. Activation of STATs 1 and 3 by OSM, LIF, and IFNg is
unaffected by preincubation with insulin or GH. Whole cell ex-
tracts were prepared from serum-deprived 3T3-L1 adipocytes following
a 20-min preincubation with either 50 nM insulin or 250 ng/ml of GH,
followed by a 15-min stimulation with OSM, LIF, and IFNg. One
hundred mg of each extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis. Samples were
processed, and results were visualized as described in the legend to Fig.
1. This is a representative experiment independently performed three
times.
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stimulated with IFNg alone, IFNg plus PD98059, and IFNg
plus PD98059 plus insulin. The top band is STAT 3, which is
both tyrosine (Tyr705)- and serine (Ser727)-phosphorylated. The
lower (faster migrating) band is STAT 3, which is only phos-
phorylated on Tyr705 and is only present with IFNg treatment.
The examination of STAT 3 serine phosphorylation was per-
formed using a phosphorylation state-specific antibody (STAT
3 p-ser), which only recognizes STAT 3 that is phosphorylated
on serine 727. Western blot analysis revealed that STAT 3 is
serine-phosphorylated to some extent in basal conditions but is
markedly enhanced with the addition of insulin and the sub-
sequent activation of MAPK (Fig. 6). This enhancement is
strikingly demonstrated with a lighter exposure of the STAT 3
p-ser blot. The ability of insulin to increase STAT 3 serine
phosphorylation is inhibited by PD98059. Also, the examina-
tion of active MAPK correlated with the enhancement of STAT
3 Ser727 phosphorylation and resulted in all of the STAT 3
protein migrating at the higher molecular weight band in both
cytosolic and nuclear extracts. Examination of STAT 1 and
MAPK in cytosolic extracts is shown to demonstrate even pro-
tein loading and the presence of unactivated proteins in un-
treated extracts. Insulin, a potent activator of MAPK, had no
effect on STAT 1 Tyr701 phosphorylation or nuclear transloca-
tion. Also, the inhibition of insulin-induced MAPK activation
by PD98059 had no effect on the IFNg-induced STAT 1 Tyr701
phosphorylation or nuclear translocation (Fig. 6). However,
treatment with insulin (either before or after acute IFNg stim-
ulation) resulted in all of the Tyr705-phosphorylated STAT 3
migrating at the higher molecular weight. Furthermore, the
ability of insulin to cause all of the STAT 3 to migrate at the
higher molecular weight due to Ser727 phosphorylation was
inhibited by PD98059 and the absence of active MAPK.
We also examined the nuclear translocation and Tyr701 and
Tyr705 phosphorylation of STATs 1 and 3 after treatment with
LIF and OSM in the presence of PD98059. Unlike IFNg, LIF
and OSM are potent inducers of MAPK. Serum-deprived adi-
pocytes were pretreated with insulin (15 min) or PD98059 (30
min) and then treated with either OSM or LIF for 15 min.
Pretreatment with either PD98059 or insulin had no effect on
either the tyrosine phosphorylation or nuclear translocation of
STATs 1 and 3 as indicated by the Western blot analysis of
nuclear extracts in Fig. 7. However, acute treatment with LIF
or OSM resulted in the exclusive presence of the higher mi-
grating band of STAT 3 phosphorylated at both Tyr705 and
Ser727. In the presence of PD98059 (with or without insulin),
however, there were two immunoreactive bands of STAT 3
present in nuclear extracts following acute LIF or OSM treat-
ment (Fig. 7). An identical pattern of STAT 3 immunoreactive
bands was also observed in cytosolic extracts (data not shown).
Immunoblotting of nuclear extracts with the STAT 3 Ser727
FIG. 6. IFNg-induced tyrosine phos-
phorylation and nuclear transloca-
tion of STATs 1 and 3 are independ-
ent of the activation of MAPK. Whole
cell, cytosolic, and nuclear extracts were
prepared from serum-deprived 3T3-L1
adipocytes following a 15-min treatment
of IFNg (100 units/ml). Some cells were
pretreated with 30 mM PD98059. Other
cells were pretreated for 15 min with 50
nM insulin. For one time point, cells were
treated with 50 nM insulin after the IFNg
treatment; this sample is indicated by an
asterisk at the top. One hundred mg of
each extract was separated by SDS-
PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis. Sam-
ples were processed, and results were vi-
sualized as described in the legend to Fig.
1. This is a representative experiment in-
dependently performed three times.
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antibody (STAT 3 p-ser) revealed that there was no STAT 3
Ser727 in the nucleus in the absence of LIF and OSM. Although
we have shown that a portion of STAT 3 is constitutively
serine-phosphorylated in basal serum-deprived adipocytes
(Fig. 7), this STAT 3 protein is located exclusively in the cytosol
as indicated by the lack of serine-phosphorylated STAT 3 in the
nucleus during unstimulated conditions (Fig. 7). The presence
of Ser727-phosphorylated STAT 3 is notably decreased in nu-
clear extracts isolated from LIF- or OSM-stimulated adipocytes
that were pretreated with PD98059. As shown in Fig. 7, West-
ern blot analysis with three different STAT 3 antibodies indi-
cates that preincubation with either PD98059 or insulin had no
effect on STAT 3 tyrosine phosphorylation and nuclear trans-
location. Although there is an equal amount of MAPK in each
nuclear sample, active MAPK was only detected in the nucleus
following insulin, LIF, or OSM treatment in the absence of
PD98059 as indicated in the bottom two panels of Fig. 7. Al-
though there is a much greater amount of MAPK in the cytosol,
the profile of active MAPK in the nuclear extracts was identical
to the pattern we observed in the cytosol (data not shown).
DISCUSSION
Of the different STAT activators we examined, IFNg, LIF,
and OSM were potent activators of tyrosine phosphorylation
and nuclear translocation of both STATs 1 and 3. A detectable
amount of STAT 3 Tyr705 phosphorylation was also observed
with acute PDGF, GH, IL-4, and IL-6 treatment. However, we
were unable to detect nuclear translocation under these condi-
tions, which may be due to the sensitivity of our detection of
STATs in nuclear extracts. Alternatively, weak activators of
STAT 3 tyrosine phosphorylation may be insufficient to result
in nuclear translocation. There is, however, no precedent for
the uncoupling of STAT tyrosine phosphorylation and nuclear
translocation.
We have observed distinct activation of STATs 1 and 3 in
adipocytes. For example, GM-CSF has been shown to induce
STATs 1 and 3 activation in polymorphonuclear leukocytes
(27), but it had no effect on the activation of these STAT
proteins in adipocytes. Both PDGF and EGF have been shown
to activate STATs 1 and 3 in various cell types (28–31). Yet, we
were unable to detect any activation of STATs 1 and 3 by EGF
in 3T3-L1 adipocytes. It was observed that EGF treatment
resulted in a dose- and time-dependent activation of p42/p44
(MAPK), indicating the efficacy and initiation of EGF receptor-
mediated signal transduction (data not shown). Although
PDGF receptor is down-regulated during 3T3-L1 differentia-
tion, this protein is still expressed in 3T3-L1 adipocytes (32),
and PDGF treatment did result in detectable levels of STAT 3
Tyr705 phosphorylation. It therefore seems unlikely that recep-
tor expression alone accounts for the lack of STAT activation in
adipocytes by EGF. It has recently been hypothesized that the
FIG. 7. LIF- and OSM-induced tyro-
sine phosphorylation and nuclear
translocation of STATs 1 and 3 are
independent of the activation of
MAPK. Nuclear extracts were prepared
from serum-deprived 3T3-L1 adipocytes
following a 15-min treatment with LIF or
OSM. Some cells were pretreated with 30
mM PD98059. Other cells were pretreated
for 15 min with 50 nM insulin in the ab-
sence or presence of PD98059. One hun-
dred mg of each extract was separated by
SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis.
Samples were processed, and results were
visualized as described in the legend to
Fig. 1. This is a representative experi-
ment independently performed three
times.
Distinct Activation of STATs 1 and 3 in Adipocytes31414
differential activation of STATs 1, 3, and 5 by EGF in various
cell types may be attributable to the use of different members
of the receptor family with different affinities for the various
STAT proteins (1). These studies and our results suggest that
activation of STATs is dependent upon other factors in addition
to the presence of the receptor and may account, in part, for the
highly specific, quantitative, and distinct activation of STATs 1
and 3 that we have observed in adipocytes.
This is the first study to demonstrate a time- and dose-de-
pendent activation of STATs 1 and 3 by LIF and IFNg in
adipocytes. Interestingly, STAT 3 is not responsive to IFNg in
some cell types (19, 20), but IFNg can activate STAT 5 in U937
cells (21). However, our results clearly demonstrate a time- and
dose-dependent activation of both STAT 3 Tyr705 phosphoryl-
ation and nuclear translocation by IFNg. In addition, IFNg
treatment did not result in the activation of either STATs 5A or
5B in adipocytes. The ability of STAT 3 to respond to IFNg in
adipocytes is probably a result of the specificity of STAT acti-
vation, which varies depending upon the cell type and may be
attributed to receptor expression, binding affinities, the pres-
ence or absence of other signaling proteins, or STAT dimer
composition.
Both LIF and OSM have been shown to induce STAT 5
activation in some cell types (8, 9, 11), but these growth factors
did not result in STAT 5 activation in adipocytes as determined
by a lack of nuclear translocation of STAT 5. However, both LIF
and OSM were capable of resulting in STAT 1 Tyr701 and STAT
3 Tyr705 phosphorylation and nuclear translocation in 3T3-L1
and native rat adipocytes. We have found that LIF and OSM
are potent inducers of STAT 3 tyrosine phosphorylation and
nuclear translocation but also result in an activation of STAT 1.
These findings are similar to those of Jenab and Morris (12),
which demonstrated considerable activation of STATs 3 by LIF
but significantly less activation of STAT 1 by LIF in rat Sertoli
cells. Quantitative activation of the JAK-STAT pathway has
also been observed in the signaling of GH, which results in 15
times more tyrosyl-phosphorylated JAK2 than either LIF or
IFNg treatment (33). Since the receptors for LIF and OSM
consist of the common signaling subunit, gp130, to which other
subunits are added to modify ligand specificity, we would hy-
pothesize that the distinct activation of STATs 1 and 3 by these
cytokines in adipocytes is due to unique ligand specificity.
We examined the ability of two adipogenic factors, GH and
insulin, to affect the IFNg-, LIF-, and OSM-induced Tyr701 and
Tyr705 of STATs 1 and 3, respectively. GH is a potent activator
of both STATs 5A and 5B in 3T3-F442 preadipocytes (34) and
3T3-L1 adipocytes (24). Insulin alone does not result in the
nuclear translocation of any adipocyte expressed STAT in
3T3-L1 adipocytes (24). Although both insulin and GH resulted
in MAPK activation, neither one of these agents resulted in an
attenuation or enhancement of STATs 1 and 3 phosphorylation
by LIF, OSM, or IFNg. However, in rat hepatoma cells, insulin
was demonstrated to antagonize the IL-6-induced activation of
STAT 3 (35). We were unable to observe any ability of insulin
to modulate STAT 3 Tyr705 phosphorylation or nuclear trans-
location in adipocytes. Our results indicate that activation of
STATs 5A and 5B by GH does not inhibit the activation of
STATs 1 and 3 and demonstrate that a number of activated
STAT family members can be present in the adipocyte nucleus
at one time.
Recent studies have indicated that MAPK (ERK1/ERK2)
may be involved in the STAT-induced regulation of transcrip-
tion and that maximal activation of STATs 1 and 3 requires
both tyrosine and serine phosphorylation (4, 36–38). A require-
ment of serine phosphorylation of STATs 1 and 3 for the for-
mation of STAT-promoter complexes has been demonstrated
for cytokines such as LIF, OSM, IL-6, and ciliary neurotropic
factor, which utilize the common signaling subunit, gp130 (36).
In addition, the activation of MAPK has been shown to be
required for the OSM-induced regulation of the matrix metal-
loproteinase gene 1 by STATs 1 and 3 (36). It has also been
clearly demonstrated that STAT 3 is serine-phosphorylated by
insulin in adipocytes (39). However, the role of STAT serine
phosphorylation is still very controversial.
Our studies, therefore, examined the activation of MAPK by
activators of STATs 1 and 3 in the presence of insulin,
PD98059, and insulin plus PD98059. We were able to deter-
mine that STAT 3 was phosphorylated to a limited extent on
Ser727 under basal conditions in adipocytes. Constitutive serine
phosphorylation of STAT 1 and 3 has also been observed in B
lymphocytes (40), and STATs 5A and 5B are constitutively
serine-phosphorylated in mammary epithelial cells (38). We
observed an insulin-dependent enhancement of STAT 3 Ser727
phosphorylation concomitant with an induction of MAPK acti-
vation. However, the phosphorylation of STAT 3 Ser727 was not
required for STAT 3 to be tyrosine-phosphorylated; nor was it
required for nuclear translocation. Clearly, our results suggest
that STAT 3 is serine-phosphorylated by MAPK in cultured
adipocytes. This is supported by a recent study that demon-
strated that the ERK family of MAP kinases, but not c-Jun
N-terminal kinase or p38, could specifically phosphorylate
STAT 3 on serine 727 in response to growth factors (41). Yet,
these data do not rule out the possibility that other kinases
may also participate in the regulation of STAT serine phospho-
rylation. We have been unable to investigate STAT-DNA bind-
ing, since the genes that STATs regulate in adipocytes have not
been identified. However, our results demonstrate that the
phosphorylation of STAT 3 Ser727 is not required for Tyr705
phosphorylation or nuclear translocation. It is well documented
that STATs must be tyrosine-phosphorylated and form dimers
prior to translocation. Our results prove that serine phospho-
rylation of STAT 3 does not affect either tyrosine phosphoryl-
ation or nuclear translocation and support a recent study that
demonstrated that serine phosphorylation has no influence on
DNA binding of either STAT 1 or 3 (10). The issue of STAT 1
serine phosphorylation is a bit more complicated than that
observed for STAT 3. To this point, the kinase responsible for
STAT 1 Ser727 phosphorylation has not been identified. In
contrast to STAT 3, STAT 1 appears to be a poor substrate for
all MAPK superfamily members (41). Also, the lack of a dis-
cernible gel shift upon serine phosphorylation would necessi-
tate that a specific STAT 1 Ser727 antibody be used. Work to
further clarify the regulation of STAT 1 Ser727 phosphorylation
is ongoing, but we have demonstrated that STAT 1 Tyr705 is
independent upon the activation of MAPK.
In summary, we have examined the tyrosine phosphoryla-
tion and nuclear translocation of STATs 1 and 3 by potent
activators of these transcription factors in fat cells. These stud-
ies have revealed that the activation of STATs 1 and 3 in
adipocytes is highly specific and significantly different from the
activation of these STATs in other cell types. These studies
provide a basis for determining the function of STATs 1 and 3
in adipocytes, since there are numerous unanswered questions
about the activation of STATs in adipocytes. For example, is
there a physiological consequence of the quantitative activation
of STATs 1 and 3 by LIF, OSM, and IFNg? To address this and
similar questions, we must identify the genes that are regu-
lated by STATs in adipocytes and examine the protein compo-
sition of STAT DNA binding complexes and their ability to
regulate transcription. We are in the process of experimentally
addressing this and other hypotheses concerning the physio-
logical activation and function of STATs in adipocytes.
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